Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Vasovist™' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Vasovist™' found in 1 term [] and 3 definitions []
1 - 4 (of 4)     
Result Pages : [1]
MRI Resources 
Databases - Abdominal Imaging - Directories - Patient Information - Pediatric and Fetal MRI - Stent
 
Vasovist™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Vasovist™ is an albumin-targeted intravascular contrast agent. It is indicated for contrast enhanced MR angiography (CE-MRA) for the visualization of abdominal or limb vessels in patients with suspected or known vascular disease. After IV injection, Vasovist™ binds reversibly to human albumin in plasma, which results in long-lasting increased relaxivity. Imaging from 5 to 50 min is possible. A small unbound portion is, by glomerular filtration, eliminated by the kidneys.
AngioMARK® was the formerly trade name and MS-325 the research name. Currently the phase III clinical trials are completed to determine its efficacy for peripheral vascular disease and coronary artery disease.
In the U.S., EPIX received an approvable letter from the U.S. Food and Drug Administration (FDA) for Vasovist™ in January 2005. In 2009, Epix Pharmaceuticals has sold the U.S., Canadian and Australian rights for its blood pool agent (now named ABLAVAR™), to Lantheus Medical Imaging, Inc..

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or the liver transplantation period.

See also MRI Safety.
Drug Information and Specification
NAME OF COMPOUND
Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, predominantly positive enhancement
20-45 mmol-1sec-1, Bo=0,47T
PHARMACOKINETIC
Intravascular, short elimination half life
825 mOsmol/kg H2O
CONCENTRATION
244 mg/mL, 0.25mmol/mL
DOSAGE
0.12 mL/kg, 0.03 mmol/kg
PREPARATION
ready to use
DEVELOPMENT STAGE
approved
DISTRIBUTOR
See below
PRESENTATION
10 mL vials
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
Vasovist™
?
?
North America, Australia
for sale
spacer
 
• Share the entry 'Vasovist™':  Facebook  Twitter  LinkedIn  
 
Further Reading:
  Basics:
EPIX Medical's new multimedia Web site features AngioMARK images in 3D
Friday, 5 March 1999
MRI technology combined with contrast agent optimizes diagnosis of cardiovascular disease
1999
MRI Resources 
Stent - Patient Information - Used and Refurbished MRI Equipment - Intraoperative MRI - Developers - Veterinary MRI
 
ABLAVAR™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
ABLAVAR™ (formerly named Vasovist™) is a blood pool agent for magnetic resonance angiography (MRA), which opens new medical imaging possibilities in the evaluation of aortoiliac occlusive disease (AIOD) in patients with suspected peripheral vascular disease.
ABLAVAR™ binds reversibly to blood albumin, providing imaging with high spatial resolution up to 1 hour after injection, due to its high relaxivity and to the long lasting increased signal intensity of blood.
As with other contrast media: the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered.

WARNING:
NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Cardiovascular Imaging, Adverse Reaction, Molecular Imaging, and MRI Safety.
Drug Information and Specification
NAME OF COMPOUND
Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, predominantly positive enhancement
20-45 mmol-1sec-1, Bo=0,47T
PHARMACOKINETIC
Intravascular
825 mOsmol/kg H2O
CONCENTRATION
244 mg/mL, 0.25mmol/mL
DOSAGE
0.12 mL/kg, 0.03 mmol/kg
PREPARATION
ready to use
DEVELOPMENT STAGE
FDA approved
DISTRIBUTOR
See below
PRESENTATION
10 mL vials
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
Approved
USA, Canada, Australia
ABLAVAR™
Approved
spacer

• View the DATABASE results for 'ABLAVAR™' (3).Open this link in a new window


• View the NEWS results for 'ABLAVAR™' (1).Open this link in a new window.
 
Further Reading:
  Basics:
Ablavar Prescribing Information
   by www.ablavar.com    
  News & More:
The first FDA-approved blood-pool MR agent offers additional time for imaging and possibly some new applications
Thursday, 1 July 2010   by www.radiologytoday.net    
MRI Resources 
Online Books - Cardiovascular Imaging - MR Guided Interventions - Open Directory Project - Raman Spectroscopy - Knee MRI
 
EPIX Pharmaceuticals, Inc.MRI Resource Directory:
 - Developers -
 
www.epixmed.com [This entry is marked for removal.]

(July 20, 2009 - EPIX Pharmaceuticals, Inc. announced today that, in light of the company's lack of capital and inability to obtain additional financing or consummate a strategic transaction, it has entered into an Assignment for the Benefit of Creditors, effective immediately, in accordance with Massachusetts law).
EPIX has been a specialty pharmaceutical firm developing targeted contrast agents to improve the capability of MRI as a diagnostic tool for a variety of diseases. Gadofosveset trisodium (formerly MS-325, Vasovist™, now ABLAVARt™), is an injectable intravascular contrast agents designed for multiple vascular imaging applications, including peripheral vascular disease and coronary artery disease. EPIX conducted a pivotal Phase III trial for the detection of peripheral vascular disease, as well as a Phase II feasibility trial for coronary artery disease diagnosis.
To ensure rapid development and adoption of gadofosveset trisodium into clinical practice upon regulatory approval, EPIX pursued an aggressive product development plan and commercialization strategy. The Company established an exclusive, worldwide sales and marketing agreement with Bayer Schering Pharma AG. EPIX also established corporate collaborations with GE Healthcare, Philips Medical Systems and Siemens Medical Systems, the three leading MRI manufacturers, which together account for approximately 80 percent of the MRI machines installed worldwide.
EPIX had other MRI contrast agents under development, most significantly a novel prototype blood clot agent (EP-2104R). Potential clinical applications for this type of agent include detection of deep venous thrombosis, pulmonary embolism and blood clots in the coronary and carotid arteries. Currently, there is no high resolution imaging technique to directly visualize blood clots in patients with suspected cardiovascular disease.
spacer

• View the DATABASE results for 'EPIX Pharmaceuticals, Inc.' (7).Open this link in a new window


• View the NEWS results for 'EPIX Pharmaceuticals, Inc.' (69).Open this link in a new window.
 
Further Reading:
  Basics:
Epix Pharmaceuticals to shut down
Tuesday, 21 July 2009   by boston.bizjournals.com    
MRI Resources 
Functional MRI - MRA - Open Directory Project - Lung Imaging - Bioinformatics - Safety Products
 
NC100150 InjectionInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Short name: NC100150, PEG-feron, generic name: Feruglose, preliminary trade name: Clariscan™
NC100150 injection is the code name for an USPIO (ultrasmall superparamagnetic iron oxide) MRI contrast agent under development. Microvessel permeability depends on functional and morphologic characteristics of cancer vessels and on physicochemical properties of the injected contrast medium molecule.
USPIO particles have a favorable pharmacological and tolerance profile and are being tested clinically of the potential for the quantitative characterization of tumor microvasculature and specifically for measures of the microvessel permeability. Iron-based products take advantage of their large molecular size, which prevents diffusion into body tissues. These agents are disposed of by the liver and spleen as particulate matter.
NC100150 Injection (Nycomed Amersham, Amersham Health ) consists of USPIO particles that are composed of single crystals (4- to 7-nm diameter) and stabilized with a carbohydrate polyethylene glycol (PEG) coat. The iron oxide particles have to be suspended in an isotonic glucose solution. The final diameter of an USPIO particle is approximately 20 nm. Blood pool half-life is more than two hours in humans; the particles are taken up by the mononuclear phagocyte system and distributed mainly to the liver and spleen.
NC100150 would compete with the contrast agents Ferumoxytol from AMAG Pharmaceuticals, Inc. and Vasovist™ from EPIX Pharmaceuticals, Inc., but at this time the development of NC100150 Injection/Clariscan™ is discontinued.
spacer

• View the DATABASE results for 'NC100150 Injection' (5).Open this link in a new window


• View the NEWS results for 'NC100150 Injection' (2).Open this link in a new window.
MRI Resources 
Mass Spectrometry - Knee MRI - Supplies - Process Analysis - Spectroscopy pool - Service and Support
 
     1 - 4 (of 4)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



MRI is trending to low field magnets :
reduced costs will lead to this change 
AI will close the gap to high field 
only in remote areas 
is only temporary 
never 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 28 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]